Home » EPIC Archives: VAL

VAL News Archives

ValiRx Plc VAL401 is going forward

Hardman & Co

ValiRx Plc (LON:VAL)  is a clinical-stage biopharmaceutical company focused on the development of therapeutics for the treatment of cancer. The company has two leading assets: VAL201 (Phase I/II) – a peptide ...

Read Article »

ValiRx Plc VAL401 Phase II trial completed

Hardman & Co

ValiRx Plc (LON:VAL) is a clinical-stage biopharmaceutical company focused on the development of therapeutics for the treatment of cancer. The company’s two leading assets are in clinical trials: VAL201 (Phase ...

Read Article »

ValiRx Plc Clinical efficacy of VAL401

Hardman & Co

ValiRx Plc (LON:VAL) is a clinical-stage biopharmaceutical company focused on the development of therapeutics for the treatment of cancer, associated biomarkers and companion diagnostics. The company’s two leading assets are ...

Read Article »

ValiRx Progressing all the pipeline

Hardman & Co

ValiRx Plc (LON:VAL) is a clinical-stage biopharmaceutical company focused on the development of therapeutics for the treatment of cancer, associated biomarkers and companion diagnostics. The company’s two leading assets are ...

Read Article »

ValiRx Positive early data from VAL401

Hardman & Co

ValiRx Plc (LON:VAL) is a clinical-stage biopharmaceutical company focused on the development of therapeutics for the treatment of cancer, associated biomarkers and companion diagnostics. The company’s two leading assets are ...

Read Article »

ValiRx Plc GeneICE and VAL101 progress

Hardman & Co

ValiRx Plc (LON:VAL) is a clinical-stage biopharmaceutical company focused on the development of therapeutics for the treatment of cancer, associated biomarkers and companion diagnostics. The company’s two leading assets are ...

Read Article »

ValiRx Plc Developing novel cancer therapies

Hardman & Co

ValiRx Plc (LON:VAL) is a clinical-stage bio-pharmaceutical company focused on the development of therapeutics for the treatment of cancer, associated biomarkers and companion diagnostics. The company’s two leading assets are ...

Read Article »